<DOC>
	<DOCNO>NCT00548327</DOCNO>
	<brief_summary>This study evaluate whether Atomoxetine improve cognition healthy volunteer well patient schizophrenia . Atomoxetine drug Food Drug Administration ( FDA ) approve Attention Deficit Disorder allegedly increase amount neurotransmitter dopamine frontal cortex brain .</brief_summary>
	<brief_title>The Effects Atomoxetine Cognition Brain Function Based Catechol-O-methyltransferase ( COMT ) Genotype</brief_title>
	<detailed_description>Psychopharmacological modulation catecholaminergic system enhance aspect cognitive function . For example , catechol-O-methyltransferase ( COMT ) inhibitor tolcapone improve work memory/executive function . Similarly , modafinil , catecholaminergic agonist norepinephrine ( NA ) reuptake block property , also show improve delay-dependent work memory mouse . Differences response individual might relate number factor , include variation gene . The recent finding polymorphism COMT gene , produce change enzyme activity , account 4 % variance performance work memory task human suggest COMT genotype may predict response COMT inhibitor dopaminergic agonist increase catecholaminergic function frontal cortex . In present investigation goal examine , normal control patient schizophrenia , effect atomoxetine , selective noradrenaline reuptake inhibitor increase extracellular level dopamine frontal cortex , cognitive function . We predict normal control patient schizophrenia val/val genotype , present high COMT activity , thus , low extracellular dopamine concentration frontal cortex , significant improvement work memory . Furthermore , conjunction National Institute Mental Health imaging protocol , would like examine neurophysiological correlate related working memory . We predict improved measure prefrontal efficiency subject patient specifically val/val genotype . The present protocol provide new insight importance genetic polymorphism regulation aminergic-controlled cognitive function normal individual . Furthermore , protocol test whether atomoxetine offer new treatment , base genotype , cognitive impairment schizophrenia . An Investigational New Drug ( IND ) waiver request present study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Memory Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>INCLUSION CRITERIA : Prior participation NIH protocol # 95M0150 , new normal volunteer schizophrenic patient meet criterion NIH protocol # 95M0150 . No active Axis I Axis II diagnosis normal volunteer . Age range : 1845 year . Normal EKG blood pressure reading . EXCLUSION CRITERIA : Normal volunteer active Axis I Axis II disorder patient Axis I diagnosis schizophrenia schizoaffective disorder obtain either prior Structured Clinical Interview Diagnostic Statistical Manual Disorders ( SCID ) interview Protocol 95M0150 screen interview exclude . Subjects history cardiovascular disease , liver disease serious medical illness , untreated uncontrolled hypertension exclude potential drugdrug interaction potential deleterious effect drug medical condition . An electrocardiogram , blood pressure , pulse rate , toxicological screen , cell blood count metabolic panel include Liver Function Tests ( LFTs ) check subject prior participation study . Any subject electrocardiogram deem abnormal cardiologist sustain systolic blood pressure 150 mmHg , diastolic blood pressure 100 mmHg exclude study . Schizophrenic patient take COMT inhibitor , illicit drug abuse , Monoamine Oxidase ( MAO ) inhibitor exclude . Patients take paroxetine , fluoxetine , bupropion , tricyclic antidepressant , albuterol , modafinil , stimulant pressor agent exclude study . No medication stop order participate study . Normal control subject take medication occasional nonsteroidal antiinflammatory drug ( NSAID ) recent history illicit drug alcohol abuse exclude . Normal control contraceptive medication exclude study . Pregnant woman : Women childbearing potential undergo urine pregnancy test day study initiate screen history possibility pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Genes</keyword>
	<keyword>Dorsolateral Prefrontal Cortex</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Functional Magnetic Resonance Imaging</keyword>
	<keyword>Neuropsychological Testing</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Atomoxetine</keyword>
	<keyword>Cognitive Study</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Normal Volunteers</keyword>
	<keyword>Catechol-O-Methyltransferase</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>